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Aim To compare four cardiovascular disease (CVD) risk mod-
els and to assess the prevalence of eligibility for lipid lower-
ing therapy according to the 2013 American College of Car-
diology/American Heart Association (ACC/AHA) guidelines, 
European AIDS Clinical Society Guidelines (EACS), and Euro-
pean Society of Cardiology and the European Atherosclero-
sis Society (ESC/EAS) guidelines for CVD prevention in HIV 
infected patients on antiretroviral therapy.
Methods We performed a cross-sectional analysis of 254 
consecutive HIV infected patients aged 40 to 79 years who 
received antiretroviral therapy for at least 12 months. The 
patients were examined at the HIV-treatment centers in 
Belgrade and Zagreb in the period February-April 2011. We 
compared the following four CVD risk models: the Framing-
ham risk score (FRS), European Systematic Coronary Risk 
Evaluation Score (SCORE), the Data Collection on Adverse 
Effects of Anti-HIV Drugs study (DAD), and the Pooled Co-
hort Atherosclerotic CVD risk (ASCVD) equations.
Results The prevalence of current smoking was 42.9%, hy-
pertension 31.5%, and hypercholesterolemia (>6.2 mmol/L) 
35.4%; 33.1% persons were overweight, 11.8% were obese, 
and 30.3% had metabolic syndrome. A high 5-year DAD 
CVD risk score (>5%) had substantial agreement with the 
elevated (≥7.5%) 10-year ASCVD risk equation score (kap-
pa = 0.63). 21.3% persons were eligible for statin therapy 
according to EACS (95% confidence intervals [CI], 16.3% 
to 27.4%), 25.6% according to ESC/EAS (95% CI, 20.2% to 
31.9%), and 37.9% according to ACC/AHA guidelines (95% 
CI, 31.6 to 44.6%).
Conclusion In our sample, agreement between the high 
DAD CVD risk score and other CVD high risk scores was not 
very good. The ACC/AHA guidelines would recommend sta-
tins more often than ESC/EAS and EACS guidelines. Current 
recommendations on treatment of dyslipidemia should be 
applied with caution in the HIV infected population.
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Observational studies found higher rates of myocardial in-
farction and cerebrovascular events in HIV infected than in 
uninfected persons (1-6). Hence, prevention of cardiovas-
cular disease (CVD) in HIV infected patients should be an 
integral part of current clinical practice. In routine HIV clini-
cal care in developed countries it is recommended to cal-
culate the CVD risk using prediction models (7-9). Prevent-
able and modifiable predisposing factors for CVD should 
be identified, and lifestyle and pharmacological interven-
tions should be undertaken.
CVD prevention in HIV-infected persons is mainly based 
on recommendations for the HIV uninfected population. 
The American College of Cardiology/American Heart As-
sociation (ACC/AHA) published the 2013 Guideline on 
the Assessment of Cardiovascular Risk (10) and the Euro-
pean Society of Cardiology and European Atherosclerosis 
Society (ESC/EAS) published one of the major European 
guidelines (11). The European AIDS Clinical Society (EACS) 
addresses many complications of HIV disease, including 
recommendations for lipid lowering therapy (7). All guide-
lines use different models for assessing cardiovascular risk. 
EACS recommends the Framingham Risk Scoring (FRS), 
while ESC/EAS recommends the European Systematic 
Coronary Risk Evaluation score (SCORE). The FRS has been 
widely used for estimation of coronary heart disease (an-
gina, myocardial infarction, and coronary death), hard cor-
onary events (myocardial infarction and coronary deaths), 
stroke, and global CVD (including CVD deaths, coronary 
disease, transient ischemic attack, and stroke) (12). SCORE 
estimates the 10-year risk of a first fatal atherosclerotic 
event (eg, myocardial infarction, stroke, aortic aneurysm), 
and calibrated versions exist to adjust for different death 
rates in European countries (13). These estimates have an 
important role in identifying high risk patients and in rec-
ommending lipid lowering therapy (7,11,14). ACC/AHA 
recommends the Pooled Cohort Equations for atheroscle-
rotic cardiovascular disease (ASCVD) risk to evaluate the 
need for treatment of blood cholesterol levels in the non-
HIV infected population (10).
CVD risk estimation formulas are primarily intended to as-
sist physicians in identifying high risk healthy persons old-
er than 40 years with no signs of clinical atherosclerotic 
disease (7,10,11,14). Patients with diabetes are generally 
recommended more intensive interventions and consid-
ered at a higher risk for CVD (11,14). Cardiovascular risk 
models designed for the HIV infected population have also 
been developed, the most widely known is the Data Col-
lection on Adverse Effects of Anti-HIV Drugs Study (DAD) 
risk equation, which also includes HIV-specific variables 
such as duration of indinavir or lopinavir use and current 
use of indinavir, lopinavir, or abacavir (15). However, the 
follow-up in the DAD Study is still relatively short and the 
DAD risk equation has yet not been formally recommend-
ed for CVD risk assessment in routine clinical care for HIV-
infected persons.
Southeastern European countries such as Bulgaria, Croatia, 
Hungary, Romania, and Serbia have high rates of age-stan-
dardized mortality from cardiovascular disease, (ie, isch-
emic heart disease and cerebrovascular disease) (16,17). 
The aim of our study was to analyze the agreement of 
the high DAD CVD score with other CVD scores (CVD-FRS, 
SCORE, ASCVD) developed for the non-HIV infected popu-
lation in HIV infected patients receiving antiretroviral thera-
py (ART) in Croatia and Serbia. We also examined the prev-
alence of eligibility for lipid lowering therapy according to 
the 2013 ACC/AHA guidelines, EACS, and European ESC/
EAS guidelines for cardiovascular disease prevention.
MethoDs
settings
The study was conducted at the University Hospital for In-
fectious Diseases, Zagreb, Croatia and the HIV/AIDS Unit, 
Institute for Infectious and Tropical Diseases, School of 
Medicine, University of Belgrade, Belgrade, Serbia, in the 
period February-April 2011. Both Croatia and Serbia have 
a low-level HIV epidemic (18,19). Croatia has a centralized 
system of care for HIV and all patients are treated in one 
center. The number of patients treated per one calendar 
year in the period 2011-2013 ranged from 650 to 780. In 
Serbia, there are currently four HIV treatment centers. The 
Institute for Infectious and Tropical Diseases, School of 
Medicine, University of Belgrade was established in 1985 
and is by far the largest one. In the period 2011-2013, it 
treated 1000 to 1200 people living with HIV per year. In 
Croatia and Serbia health care insurance is universal and 
free of charge, however, the number of approved antiretro-
virals is limited, and older, less lipid friendly antiretrovirals, 
are still being used (20,21).
study population
We collected data on risk factors for CVD for all consec-
utive HIV infected patients seen at a scheduled visit for 
routine follow-up in the two centers. We included per-
sons 40 to 79 years old in whom lipid measurements 
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were done and who had at least 12 months of antiretrovi-
ral therapy (ART). We excluded pregnant women and pa-
tients with acute illness or exacerbation of a chronic illness 
at the time of evaluation. A total of 355 persons were seen 
at the treatment center in Zagreb, 132 of whom met our 
eligibility criteria. At the treatment center in Belgrade 712 
persons were examined, 122 of whom met our eligibility 
criteria.
A standardized data collection form was developed 
which included information on sociodemographic char-
acteristics, HIV disease characteristics (current CD4 cell 
count, HIV-1 viral load, past and current history of ART), 
known risk factors for CVD (family history of premature 
CVD, smoking, hypertension, age, sex), lipids (total cho-
lesterol, HDL-cholesterol, LDL-cholesterol and triglycer-
ide), blood glucose measurements, and hepatitis B and C 
coinfection. The study was approved by the Ethics Com-
mittee of the University Hospital for Infectious Diseases, 
Zagreb, Croatia and the Clinical Center of Serbia Ethics 
Committee.
Definitions
CVD was considered present if a history of any of the fol-
lowing conditions existed on inclusion into the study: 
myocardial infarction, stable/unstable angina, invasive 
coronary artery procedure, carotid artery disease (symp-
tomatic [eg, transient ischemic attack or stroke] or >50 
percent stenosis on angiography or ultrasound), stroke, 
peripheral artery disease, abdominal aortic aneurysm or 
other forms of clinical atherosclerotic disease (eg, renal ar-
tery disease). Family history of premature cardiovascular 
events was considered present if the event occurred in a 
male first-degree relative <55 years or female first-degree 
relative <65 years. Diabetes mellitus was defined if at least 
two fasting plasma glucose levels were ≥7.0 mmol/L, ca-
sual plasma glucose >11.1 mmol/L, or if patient had a his-
tory of diabetes treatment.
Arterial hypertension was defined as systolic blood pres-
sure >140 mm Hg and/or diastolic blood pressure >90 
mm Hg (>135/85 mm Hg in diabetic patients) or taking 
antihypertensive drugs. Blood pressure was measured by 
the attending nurse using mercury sphygmomanometers. 
The patient was in a seated position; his or her arm was 
supported and flexed at the level of the heart. The stetho-
scope's bell was lightly pressed over the brachial artery 
just below the cuff's edge. The first knocking sound 
(Korotkoff ) indicated the patient's systolic pressure 
and the disappearance of the knocking sound indicated 
diastolic pressure.
Dyslipidemia was considered present if total cholesterol 
>6.2 mmol/L, HDL-cholesterol <1.03, or fasting triglycer-
ides >2.26 mmol/L. We used the modified updated Nation-
al Cholesterol Education Program criteria for the definition 
of metabolic syndrome: triglycerides of at least 1.7 mmol/L, 
HDL of 1.0 mmol/L or less in men and of 1.3 mmol/L or less 
in women, hypertension (systolic blood pressure >130 mm 
Hg or diastolic blood pressure >85 mm Hg), or use of an-
tihypertensive medications and a glucose level at least 5.6 
mmol/L or the diagnosis of diabetes. Body mass index was 
used as a surrogate for waist circumference (22).
Ten-year risk for CVD was calculated using the Framingham 
equation (23) available as a web-based tool (http://hivpv.
org/Home/Tools). The score was categorized as follows: 
<10% – low risk; 10%-20% – moderate risk; ≥20% – high 
risk. We also calculated the SCORE, which evaluates the 10-
year risk of the first fatal atherosclerotic event (for exam-
ple, myocardial infarction, stroke, and aortic aneurysm). We 
used the SCORE equation for high-risk countries, since the 
guidelines consider Croatia and Serbia as high-risk coun-
tries (13). Persons were considered at low risk if the score 
was <1%, at moderate risk if score was 1%-5%, and at high 
risk if the score was ≥5%. We applied the DAD risk equa-
tion exactly as published (15); a 5-year CVD risk >5% was 
considered high. The Pooled Cohort equation for ASCVD 
was calculated according to instructions in the 2013 ACC/
AHA Guideline on the Treatment of Blood Cholesterol (10). 
The information required to estimate ASCVD risk includes 
age, sex, race, total cholesterol, HDL-cholesterol, systolic 
blood pressure, antihypertensive drug use, diabetes, and 
smoking status. The score estimates a 10-year risk for AS-
CVD for men and women 40 to 79 years of age. The analysis 
of agreement of high risk scores derived from the different 
CVD risk models included 213 individuals without known 
CVD events, without diabetes, and with total serum cho-
lesterol ≤8 mmol/L and LDL-cholesterol ≤4.9 mmol/L.
Eligibility for lipid lowering therapy was assessed in 211 
persons not receiving lipid lowering agents. We used three 
different guidelines; EACS, ESC/EAS, and the ACC/AHA 
guidelines. The current EACS guidelines use the CVD-FRS 
for defining eligibility for lipid lowering therapy. Therapy 
is recommended in patients with established CVD, diabe-
tes, or 10-year CVD-FRS≥20% (7). We considered persons 
eligible for lipid lowering therapy according to the ESC/
EAS guidelines if they already had a CVD event, diabetes, 
17Begovaac et al: Comparison of four international cardiovascular disease prediction models in HIV infected patients
www.cmj.hr
or total cholesterol ≥8 mmol/L (11). Individuals were also 
considered to be eligible if the calculated SCORE value 
was between 5 and 10% and the LDL-cholesterol was ≥2.5 
mmol/L or the SCORE value was ≥10% and LDL-cholesterol 
was ≥1.8 mmol/L (11). Individuals in whom therapy is “con-
sidered” by the ESC/EAS guidelines were classified in the 
“not recommended” group. According to the 2013 ACC/
AHA guidelines, individuals with the following conditions 
are eligible for lipid-lowering therapy: 1) presence of CVD, 
2) primary elevations of LDL-C≥4.9 mmol/L, 3) diabetes 
with LDL-C 1.8 to 4.9 mmol/L, and 4) an LDL-C level 1.8 to 
4.9 mmol/L with an estimated 10-year ASCVD risk of ≥7.5% 
and without established CVD or diabetes (10).
statistical analysis
Continuous variables were presented as medians and the 
first to third quartile (Q1-Q3) range. Categorical variables 
were presented as frequencies with percentages. The 
Agresti- Coull method was used for calculating 95% con-
fidence intervals (CI) for proportions. We evaluated agree-
ment between different high cardiovascular risk scores in 
a subset of 213 non-diabetic persons without a history of 
cardiovascular events and total cholesterol ≤8 mmol/L and 
LDL-cholesterol ≤4.9 mmol/L. This agreement was evaluat-
ed using the following cut-offs: 10-year CVD-FRS≥20%, 10-
year SCORE≥5%, 10-year ASCVD risk ≥7.5%, and DAD CVD 
score >5%. Agreement between these categorized cardio-
vascular risk scores was assessed by observed agreement, 
agreement for higher and lower scores, and the Cohen’s 
kappa (ĸ) statistics. The delta method suggested by Mackin-
non (24) was used for calculating the 95% CI for agreement 
for higher and lower scores. Patients who already used sta-
tins were not evaluated for the eligibilty for lipid lowering 
therapy (n = 43). Agreement for the eligibility for lipid lower-
ing therapy by the EACS, ESC/EAS, and ACC/AHA guidelines 
was also assessed by ĸ statistics. The level of agreement was 
considered poor if ĸ = 0.20, fair if ĸ = 0.21-0.40, moderate if 
ĸ = 0.41-0.60, substantial if ĸ = 0.61-0.80, and very good if 
ĸ>0.80. All statistical analyses were done using SAS soft-
ware, version 9.3. (SAS Institute, Cary, NC, USA).
ResuLts
A total of 254 patients (122 from Serbia and 132 from Croa-
tia) were included in the study. (Table 1). Of 254 persons, 
193 (76%) were men. Of 61 women, 43 (70.5%) were from 
Belgrade. Women were younger than men (median 47 vs 
50 years). All study participants were Caucasians.
The prevalence of high CVD scores or risk equivalents was 
noticeable and it ranged from 27.2% (69 of 254) for the 
CVD-FRS to 51.6% for the DAD score (131 of 254) (Table 2, 
Figure 1). Of note, 58.3% of persons had a CVD-FRS>10%, 
71.5% of persons had a SCORE>1%, and 98.4% had a DAD 
score >1%. Current use of abacavir and the use of protease 
inhibitors contributed significantly to the high DAD CVD 
risk score (Table 2). Of 254 persons, 84 (33.1%) were over-
weight (body mass index, 25-29.9) and 30 (11.8%) were 
obese. A clinical CVD event was present in 8 persons (myo-
cardial infarction, 6; stroke, 1; and coronary angiography 
with stenting, 1) and diabetes in 10.
We evaluated agreement between the high 5-year CVD 
DAD score and the 10-year CVD-FRS, 10-year CVD SCORE, 
and 10-year ASCVD risk score in 213 non-diabetic per-
taBLe 1. Major hIV-disease characteristics of 254 hIV infected persons from Croatia and serbia*
Characteristics total (N = 254) serbia (N = 122) Croatia (N = 132)
Mode of transmission
Men who have sex with men  75 (29.5)  11 (9.0)  64 (48.5)
Sex between men and women  94 (37.0)  41 (33.6)  53 (40.2)
Intravenous drug use  22 (8.7)  15 (12.3)   7 (5.3)
Other/unknown  63 (24.8)  55 (45.1)   8 (6.1)
Current CD4 cell count, mm3 484 (311-661) 452 (274-674) 507.5 (365-658)
Current viral load†
HIV-1 RNA<200 copies/mL 242 (97.2) 115 (98.3) 127 (96.2)
HIV-1 RNA≥200 copies/mL   7 (2.8)   2 (1.7)   5 (3.8)
Current use of abacavir  79 (64.8) 138 (54.3)  59 (44.7)
Current use of lopinavir/ritonavir  94 (37.0)  47 (38.5)  47 (35.6)
Has antibody to hepatitis C virus  30 (11.8)  16 (13.1)  14 (10.6)
Hepatitis B surface antigen positive  19 (7.5)  12 (9.8)   7 (5.3)
*Values are n (%) or medians (Q1-Q3).
†5 patients from serbia had no viral load measurement.
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sons without a history of cardiovascular events and se-
rum cholesterol ≤8 mmol/L and serum LDL-cholesterol 
<4.9 mmol/L (Table 3). The agreement between the 5-year 
CVD DAD score and 10-year ASCVD risk score was better 
(ĸ = 0.63) than between the DAD score and CVD-FRS or 
SCORE algorithms (ĸ = 0.47 for both) (Table 3).












Age, years  49 (44-55) 57 (52-64) 57 (52-64) 55 (49-61)  54 (49-60)
Sex, male 193 (76.0) 65 (94.2) 72 (90.0) 95 (86.4) 114 (87.0)
Hypertension >140/90 or >135/85 mm Hg if diabetic  80 (31.5) 38 (55.1) 38 (47.5) 49 (44.5)  54 (41.2)
Diabetes mellitus  10 (3.9) 10 (14.5) 10 (12.5) 10 (9.1)  10 (7.6)
Current smoker 109 (42.9) 40 (58.0) 39 (48.8) 59 (53.6)  75 (57.3)
Ex-smoker  78 (30.7) 13 (18.8) 19 (23.8) 24 (21.8)  35 (26.7)
Cholesterol >6.2 mmol/L  90 (35.4) 29 (42.0) 41 (51.3) 55 (50.0)  60 (45.8)
HDL-C<1.03 mmol/L for men and <1.3 women  63 (24.8) 15 (21.7) 11 (13.8) 27 (24.5)  29 (22.1)
Triglycerides >2.26 mmol/L  96 (37.8) 34 (49.3) 33 (41.3) 61 (46.4)  61 (46.6)
Dyslipidemia¶ 164 (64.6) 48 (69.6) 55 (68.8) 82 (74.6)  84 (71.8)
Family history of cardiovascular disease  20 (7.9)  3 (4.3)  3 (3.8)  5 (4.5)   7 (5.3)
Metabolic syndrome  77 (30.3) 30 (43.5) 29 (36.3) 41 (37.3)  47 (35.9)
Body mass index (kg/m2)  24.5 (22.3-27.3) 25.1 (23.5-27.8) 25.1 (23.5-27.8) 25.1 (22.9-28)  24.6 (22.8-27.6)
Current use of protease inhibitors 145 (57.1) 36 (52.2) 42 (52.2) 64 (58.2)  89 (67.9)
Current use of abacavir 138 (54.3) 43 (62.3) 50 (62.5) 68 (61.8)  91 (69.5)
Duration of protease inhibitor use, years   2 (0-6)  3 (1-5.6)  3 (1-5.6)  2.5 (0.9-6)   4 (1.1-6)
Duration of antiretroviral therapy, years   6 (3.5-10.4) 6 (4-10.1)  6 (4-10.1)  6 (3.6-10.6)   6.5 (4.1-11)
Current use of lipid lowering agents  43 (16.9) 24 (34.8) 24 (30.0) 30 (27.3)  33 (25.2)
Current use of antihypertensive medications  49 (19.3) 24 (34.8) 22 (27.5) 31 (28.2)  35 (26.7)
*FRs – 10-year Framingham Risk score; sCoRe – 10-year european systematic Coronary Risk evaluation score; DaD – 5-year Data Collection on adverse 
effects of anti-hIV Drugs study score; asCVD – 10-year atherosclerotic Cardiovascular Disease Risk equation. hDL-C – high-density cholesterol.
†Values are n (%) or medians (Q1-Q3).
‡also included patients with diabetes and clinical events.
§also included patients with diabetes, clinical events and serum cholesterol >8 mmol/L.
IIall patients in the four major statin benefit groups were considered to have an elevated CVD risk.
¶Dyslipidemia, any of the following: cholesterol >6.2 mmol/L or C<1.03 mmol/L for men and <1.3 women or triglycerides >2.26 mmol/L.
taBLe 3. agreement between the 5-year DaD high CVD score and other high cardiovascular risk scores in 213 individuals between 
40 to 79 years of age*†‡§
5-year DaD CVD score observed agreement for agreement for
Cardiovascular risk scores ≤5% >5% agreement higher scores lower scores Kappa
10-year CVD-FRs
<20% 114 52 0.75 (0.68-0.80) 0.63 (0.53-0.72) 0.81 (0.76-0.86) 0.47 (0.36-0.57)
≥20% 2 45
10-year sCoRe
<5% 114 52 0.75 (0.68-0.80) 0.63 (0.53-0.72) 0.81 (0.76-0.86) 0.47 (0.36-0.57)
≥5% 2 45
10-year asCVD
<7.5% 110 32 0.82 (0.76-0.87) 0.77 (0.70-0.84) 0.85 (0.81-0.90) 0.63 (0.53-0.73)
≥7.5% 6 65
*CVD – cardiovascular disease; FRs – Framingham Risk score; asCVD – atherosclerotic cardiovascular disease; sCoRe – european system for Cardiac 
operative Risk evaluation.
†Values are frequencies or proportions with 95% confidence intervals in parenthesis.
‡analysis included individuals without a prior CVD event, with total serum cholesterol ≤8 mmol/L, LDL-cholesterol ≤4.9 mmol/L, and those who did 
not have diabetes.
§observed agreement = (a + d)/N; agreement for higher scores = (2*d)/(N-a + d); agreement for lower scores = (2*a)/(N+a-d); the letters denote cells in 
a 2 × 2 table (a, upper left; b, upper right; c, lower left; d, lower right; N = 213).
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EACS guidelines would recommend lipid lowering therapy 
to 21.3% of persons (95% CI, 16.3% to 27.4%; n = 211); ESC/
EAS guidelines to 25.6% (95% CI, 20.2% to 31.9%; n = 211); 
and ACC/AHA guidelines to 37.9% (95% CI, 31.6% to 44.6%; 
n = 211) (Figure 1). The use of ACC/AHA guidelines would 
increase the number of persons eligible for lipid lowering 
therapy by 77.8% (95% CI, 63.6%-87.6%) compared to the 
EACS guidelines that use the CVD-FRS score. The agree-
ment between the guidelines in terms of indication for lip-
id lowering therapy was ĸ = 0.61, 95% CI, 0.51-0.72 (ACC/
AHA vs EACS); ĸ = 0.71, 95% CI, 0.61-0.81 (ACC/AHA vs ESC/
EAS); and ĸ = 0.71, 95% CI, 0.60-0.82 (EACS vs ESC/EAS). The 
use of abacavir in persons with high CVD risks was quite 
frequent ( ~ 60 to 70%) and the use of lopinavir/ritonavir 
was ~ 30% (Table 2).
DIsCussIoN
We found a relatively high number of patients who need-
ed interventions to reduce their cardiovascular disease 
risks. About one fifth to more than one third of patients, 
depending on the risk equation used, needed inten-
sive lifestyle modifications (cessation of smoking, diet, or 
weight loss) and lipid lowering therapy. The agreement be-
tween the high DAD CVD scores and the elevated ASCVD 
scores was substantial (ĸ = 0.63), however, the agreement 
between high DAD and high CVD-FRS, and the high DAD 
with high SCORE algorithm was only moderate (ĸ = 0.47). 
Hence, none of the agreements were very good (ĸ>0.80). 
Agreement for lower CVD scores was better than for higher 
scores (Table 3).
Although high CVD scores are used to make clinical deci-
sions about initiating statin therapy, concordances of those 
high score categories derived from different algorithms 
have not, to our knowledge, been reported in the HIV in-
fected population. De Socio et al reported data on cardio-
vascular risk profiles using different risk models in 2007 (25) 
and 2008 (26). They found more men in the high Framing-
ham coronary heart disease risk strata (>20%) than in the 
high SCORE algorithm group (>5%) (26). However, it is dif-
ficult to compare different studies because they include 
different populations and use different risk algorithms. For 
example, in the study by De Socio et al the mean age was 
43 years and the mean SCORE percentage was 1.1. In our 
study, the mean age was 50.3 years and the mean SCORE 
percentage was 3.3. Also, the study by De Socio et al had 
been done before the DAD algorithm was developed.
CVD prediction algorithms have been developed with 
the purpose of identifying persons without known CVD 
who are at high risk of a cardiovascular event. They 
FIGuRe 1. Prevalence of high cardiovascular disease risk 
scores or risk equivalents (FRs≥20%, sCoRe≥5%, asCVD≥7.5% 
and DaD>5%) according to different algorithms (A) in 254 
participants and treatment recommendations for statin use 
(n = 211), based on the eaCs, esC/eas, and the 2013 aCC/aha 
guidelines (B). Patients with diabetes and clinical events were 
considered at high risk in the FRs and sCoRe model. Patients 
with serum cholesterol >8 mmol/L were also in the high risk 
category in the sCoRe model. all patients in the four major 
statin benefit groups were considered to have a high CVD 
risk. Patients who already used statins were not evaluated for 
eligibility for lipid lowering therapy (n = 43). *Includes partici-
pants in whom statin treatment was considered. FRs – 10-year 
Framingham Risk score; sCoRe – 10-year european systematic 
Coronary Risk evaluation score; DaD – 5-year Data Collection 
on adverse effects of anti-hIV Drugs study CVD score; asCVD 
– 10-year atherosclerotic cardiovascular disease risk equation; 
eaCs – european aIDs Clinical society; esC/eas – european 
society of Cardiology/european atherosclerotic society; aCC/
aha – american College of Cardiology/american heart as-
sociation; CVD – cardiovascular disease.
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aim to aid physicians to decide when and how to use lipid 
lowering drugs. However, there is currently no consensus 
on which CVD risk algorithm should be used in the HIV in-
fected population. The EACS guidelines recommend statin 
therapy, in addition to lifestyle modifications, when the 10-
years CVD-FRS is ≥20% (7). However, it has been reported 
that the FRS underestimates the occurrence of stroke (27) 
and myocardial infarction (28) in HIV infected patients. For 
the treatment of high blood cholesterol in the non-HIV 
infected population the use of the ASCVD algorithm has 
been recently suggested (10).
In our population of HIV infected patients without previ-
ous use of lipid lowering medications, we found that the 
recent ACC/AHA guideline would recommend statin ther-
apy to 38% of persons. The application of the 2013 ACC/
AHA guidelines that use the ASCVD score compared to 
the EACS guidelines that use the CVD-FRS would increase 
the number of eligible patients for lipid lowering therapy 
by 78%. The new cholesterol guidelines have also been 
recently compared to other guidelines in the non-HIV 
infected population (29). An analysis of 4209 individuals 
not receiving statins in the prospective Rotterdam cohort 
aged >55 years found that the new cholesterol guidelines 
would have recommended statins to 96% of men and 
66% of women (29). Of note, 66.1% of men and 39.1% of 
women were included in the “treatment recommended” 
category by the ESC/EAS guidelines (29). In a recent study, 
Zanni et al compared the 2013 ACC/AHA guidelines with 
the 2004 Adult treatment Panel III Cholesterol guidelines 
in HIV infected patients with or without subclinical high 
risk coronary plaque (30). Similarly to our findings, the 
2013 ACC/AHA cholesterol guidelines recommended sta-
tin therapy to a higher percentage of patients than 2004 
guidelines (30).
The prevalence of cardiovascular risk factors in our sam-
ple of HIV infected patients from Croatia and Serbia was 
high: hypertension (31.5%), smoking (41.9%), past smoking 
(30.7%), dyslipidemia (64.6%), and overweight or obesity 
(44.9%). The prevalence of hypertension and dyslipidemia 
was higher or similar to recent studies from the USA (31), 
Switzerland (32,33), Italy (34), and Germany (35).
The increased risk of CVD among HIV infected people is as-
sociated with traditional factors such as age, male sex, hy-
pertension, smoking, diabetes mellitus, pre-existing CVD, 
and hypercholesterolemia as in the general population 
(36). However, HIV infection itself is a CVD risk factor for 
subclinical atherosclerosis and clinical cardiovascular 
events (37-40). A low CD4+ cell count was found to be a 
risk factor for cardiovascular disease events (41,42). Certain 
drugs used for HIV treatment, eg, lopinavir/ritonavir, indi-
navir/ritonavir, amprenavir, and fosamprenavir have also 
been associated with an increased risk for myocardial in-
farction (43,44). There is a considerable controversy about 
the association of abacavir with CVD (44,45), and guide-
lines caution about abacavir use in patients with a high 
CVD risks (7). In our study, about 60% of patients with a 
high CVD risk were using abacavir. Given the unclear re-
lationship between abacavir and CVD events (44,45), it 
seems prudent to avoid using abacavir in patients with 
high cardiovascular risk if other alternatives exist. However, 
in Croatia and Serbia abacavir is frequently used due to the 
unavailability of tenofovir in Serbia and higher cost of ten-
ofovir-based formulations compared to abacavir formula-
tions in Croatia.
Our study has several limitations. Due to cross-sectional 
design, there is a lack of data on the changes in CVD risk 
over time. The analysis included only patients between 
40 and 79 years old, so the frequency of CVD risks might 
be higher than in the studies that included younger age 
groups. However, the age range we used is the age range 
in which different CVD risk equations have been primar-
ily developed and validated. Different CVD scores can also 
be compared as interval variables with graphs such as the 
Bland-Altman graph (46). However, as interventions to re-
duce CVD risks are usually made by some cutoffs we de-
cided to compare CVD risk models by the cutoff at which 
more intensive interventions are recommended. We were 
also unable to make a more detailed analysis of wheth-
er the targets for lipids or blood pressure were reached 
in patients using lipid lowering or blood pressure lower-
ing therapy. Our study sample was not large and included 
only Caucasian individuals. Finally, our point prevalences 
of different cardiovascular risk factors should be interpret-
ed with caution because of the convenience sampling 
method used.
Our data suggest that clinicians have to make decisions 
on lipid lowering therapy using inconsistent recommen-
dations. Until more data with clinical outcomes becomes 
available, physicians need to decide which of the different 
available algorithms is best for predicting CVD events in 
their patients. We would prefer to use an algorithm and 
recommendations specifically developed for the HIV pop-
ulation. It also has to be remembered that the interpreta-
tion of a particular CVD risk algorithm should always in-
clude careful clinical assessment and judgment.
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